Number of ongoing Clinical Trials (for drugs) involving Epilepsy by Phase

  • There are currently 257 ongoing clinical trials involving Epilepsy

  • Of the 257 trials,92 trials are in Phase II

  • Furthermore, 60 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Epilepsy by Phase

Published: Oct 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Epilepsy, a Central Nervous System disorder. The highest number of ongoing clinical trials involving Epilepsy is in Asia-Pacific. North America and Europe are among some of the other prominent regions involved in Epilepsy-related drug trials.

UCB SA.: The leading ongoing Epilepsy-related clinical trials sponsor

UCB SA, the Belgium-based pharmaceutical company, is the top sponsor for Epilepsy-related ongoing clinical trials.

Eisai Co Ltd, SK Biopharmaceuticals Co Ltd, Zogenix Inc, Xenon Pharmaceuticals Inc, Marinus Pharmaceuticals Inc, and Xuanwu Hospital Capital Medical University are a few other notable sponsors involving Epilepsy.

 A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Epilepsy

Lacosamide (Vimpat), Levetiracetam (Keppra, Kepcet, E Keppra), and Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar) are among the key marketed drugs involving Epilepsy.

Lacosamide (Vimpat), a Dihydropyrimidinase Related Protein 2 Inhibitor; Voltage-Gated Sodium Channel (SCN) Blocker, is indicated as adjunctive therapy and monotherapy for the treatment of partial-onset seizures in adults with epilepsy. The drug is marketed globally including in the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including UCB Inc. Lacosamide was first approved in 2008 and formulated as film-coated tablets, coated tablets, and syrup for oral route of administration and solution for intravenous route of administration.

Levetiracetam (Keppra, Kepcet, E Keppra), a Synaptic Vesicle Glycoprotein 2A Binder; Voltage Dependent N-Type Calcium Channel Subunit Alpha 1B Blocker, is indicated for the treatment of epilepsy, generalized seizures, generalized tonic-clonic seizure, myoclonic seizures, partial seizure (including secondary generalized seizure) and also for partial seizures in children. The drug is marketed globally including in the US, the UK, France, Germany, China, and Japan by several prominent pharma giants including UCB Inc. Levetiracetam was first approved in 1999 and formulated as film-coated tablets, solutions for oral administration, and injection solution concentrate for intravenous route of administration.

Looking to discover more data & insights?

Sign up for a free account to monitor sector landscapes, pinpoint market trends & more.

Single License £500 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions

Related Data & Insights

Number of ongoing Clinical Trials (for drugs) involving Ankylosis by Phase

Number of ongoing Clinical Trials (for drugs) involving Enterobacteriaceae Infections by Phase

Number of ongoing Clinical Trials (for drugs) involving Peritonsillar Abscess by Phase

Number of ongoing Clinical Trials (for drugs) involving Renal Insufficiency by Phase

Number of ongoing Clinical Trials (for drugs) involving Toxoplasmosis Encephalitis by Phase

Related Companies

McKesson Corp

United States of America

Johnson & Johnson

United States of America

Pfizer Inc

United States of America

HCA Healthcare Inc

United States of America

AbbVie Inc

United States of America

Novartis AG

Switzerland

Bayer AG

Germany

Merck & Co Inc

United States of America

GSK plc

United Kingdom

Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer